Grunenthal
is a Germany-based pharmaceutical company that develops and markets pain management products for patients worldwide... Read moreGrunenthal
is a Germany-based pharmaceutical company that develops and markets pain management products for patients worldwide... Read more
News
Mar 02, 2026
FinanzNachrichten
Grunenthal: Grunenthal Group: Grnenthal takes full ownership of Grnenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Feb 24, 2026
FinanzNachrichten
Grunenthal: Grnenthal Group: Grnenthal licenses exclusive Australian rights to Qutenza to Clinect
Feb 18, 2026
FinanzNachrichten
Grunenthal: Grnenthal Group: Grnenthal's proprietary NaV 1.8 inhibitor enters clinical development
Feb 06, 2026
Pharmaceutical Business Review
Grunenthal: Apotex and Grnenthal sign deal for Nebido Canadian distribution
Nov 14, 2025
FinanzNachrichten
Grunenthal: EQS-News: Grnenthal GmbH: Grnenthal announces pricing of bond extension
Jun 03, 2025
Manufacturing Chemist
Grunenthal: Grnenthal gains rights Eli Lilly's erectile dysfunction drug Cialis across Latin America
Jun 02, 2025
FinanzNachrichten
Grunenthal: Grnenthal Group: Grnenthal announces acquisition of the rights to Cialis from Lilly in Mexico, Brazil & Colombia
Mar 03, 2025
PharmaTimes
Grunenthal: Professor Dr Uli Brdl
Feb 24, 2025
Business Mole
Grunenthal: Grnenthal grants Apotex exclusive rights to Qutenza in Canada
Jan 09, 2025
FinanzNachrichten
Grunenthal: Grnenthal Group: Grnenthal appoints Prof. Dr. Uli Brdl as Chief Scientific Officer
Grunenthal Competitors
1
2
3
4
5
6
7
8
9
10